Ceftaroline in the Treatment of Bone and Joint Infections

NCT02005068 Phase 4 WITHDRAWN

This is a study to evaluate the efficacy of Ceftaroline in the treatment of bone and joint infections.

Details

Lead sponsor	Orlando Health, Inc.
Phase	Phase 4
Status	WITHDRAWN
Start date	2013-04
Completion	2014-07

Conditions

• Osteomyelitis
• Joint Infections

Interventions

• Ceftaroline

Primary outcomes

• Sustained clinical remission from the treated osteoarticular infection — 1 year after study drug completion
  Sustained clinical remission is defined by the absence of either clinical or microbiological evidence of failure at 1 year after study drug completion, in patients who complete the protocol's antibiotic regimen(s) and did not require subsequent antibiotics for their osteoarticular infection beyond the protocol prescribed regimen.

Countries

United States